PLUS1
241.58
-1.65 (-0.68%)
-1.65 (-0.68%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NVAX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.65 | -0.68% | 241.58 | 12:26:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 242.95 | 234.2101 | 247.9385 | 243.23 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 241.55 | 241.80 | 0.25 | - | 1 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 16,776 | 997,592 | $ 240.09 | $ 239,514,746 | 3,762,234 | 6.77 - 331.5388 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:26:07 | 100 | $ 241.58 | USD |
Novavax Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 15.38B | 63.66M | 63.45M | $ 18.66M | $ - | -5.62 | -24.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Novavax News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/24/2021 | 04:14 | Dow Jones News | How Will Covax Deliver Covid-19 Vaccines to Poorer.. |
| 2/23/2021 | 13:43 | Dow Jones News | Correction to Covid-19 Vaccine Rival Drugmakers Article |
| 2/23/2021 | 07:29 | Dow Jones News | To Make More Covid-19 Vaccines, Rival Drugmakers Team Up |
| 2/22/2021 | 07:58 | Seeking Alpha | Novavax completes enrollment in U.S. COVID-19 vaccine trial |
| 2/22/2021 | 07:00 | GlobeNewswire Inc. | Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine.. |
| 2/21/2021 | 05:20 | TipRanks | Novavax Inks Gavi Supply Agreement For 1.1B COVID-19 Vaccine.. |
| 2/20/2021 | 23:18 | Seeking Alpha | A new model shows U.S. could reach COVID-19 herd immunity by.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVAX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 250.32 | 292.00 | 212.77 | 257.53 | 3,078,438 | -8.74 | -3.49% |
| 1 Month | 124.06 | 331.5388 | 121.74 | 248.31 | 6,499,592 | 117.52 | 94.73% |
| 3 Months | 121.01 | 331.5388 | 107.08 | 186.10 | 4,631,397 | 120.57 | 99.64% |
| 6 Months | 131.56 | 331.5388 | 76.6301 | 140.65 | 4,679,276 | 110.02 | 83.63% |
| 1 Year | 8.305 | 331.5388 | 6.77 | 84.43 | 6,965,697 | 233.28 | 2,808.85% |
| 3 Years | 47.20 | 331.5388 | 3.54 | 47.67 | 6,298,428 | 194.38 | 411.82% |
| 5 Years | 95.60 | 331.5388 | 3.54 | 47.19 | 6,909,604 | 145.98 | 152.7% |
Novavax Description
| Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. |
